-
Haisco submits a marketing application for the fourth indication of cyclopofol injection
Time of Update: 2021-08-10
On June 30, Haisco issued an announcement stating that its innovative drug cyclopofol injection for the indication of "general anesthesia induction and maintenance" has been recently accepted by the Drug Evaluation Center of the China National Medical Products Administration .
-
Simcere introduces 2 Alzheimer's disease drug candidates
Time of Update: 2021-08-10
They are the N3pE-targeted oral small molecule glutamyl peptide cyclotransferase in clinical phase 2b ( QPCT) inhibitor varoglutamstat (PQ912), and the monoclonal N3pE antibody PBD-C06 in the preclinical research stage .
-
The latest announcement: There are more than 560,000 pharmacies nationwide
Time of Update: 2021-08-10
The report pointed out that during the reporting period, the provincial and sub-provincial regulatory agencies inspected 5,159 pharmaceutical wholesale companies, found 701 companies that violated the relevant management regulations on drug business, and completed 610 rectifications .
-
JAK inhibitor is blocked again!
Time of Update: 2021-08-10
Pfizer's JAK inhibitor Xeljanz, in a post-marketing study for patients with rheumatoid arthritis, discovered dangerous cardiac side effects and additional risks of cancer, which caused the FDA to raise safety concerns about JAK inhibitor drugs .
-
Seeing "Made in China" from a single drug-a leap from generic drugs to independent innovation
Time of Update: 2021-08-10
As the "national team" for drug research and development, the new crown vaccine developed by Sinopharm was included in the WHO emergency use list on May 7.
-
The fifth batch of national procurement is about to implement the prices of these drugs will rise instead of falling
Time of Update: 2021-08-10
Why is the price of the same product slightly higher than the drug purchase website after the "super buyer" of the National Medical Insurance Bureau enters the market?An industry insider explained to Cyberlan that consistency evaluation is the threshold for generic drugs to participate in centralized procurement .
-
Resistance mutation mechanism of KRAS G12C inhibitor
Time of Update: 2021-08-10
On June 24, in a study on the mechanism of KRAS G12C acquired drug resistance published in the New England Journal of Medicine, researchers at the Dana-Farber Cancer Institute revealed multiple mechanisms by which cancer cells develop drug resistance .
-
Hengrui Medicine: HR17031 injection obtained the qualification of US FDA clinical trial
Time of Update: 2021-08-10
On July 1, Hengrui Pharmaceutical announced that the drug HR17031 injection has obtained the clinical trial qualification of the US FDA and is intended to be used for the treatment of type 2 diabetes .
S. dollars, and the global sales of Soliqua 100/33 will be approximately 184 million U.
-
Accelerate the development of mRNA vaccines Sanofi plans to develop 6 clinical-phase candidate products within 4 years
Time of Update: 2021-08-10
On June 29, 2021, Sanofi announced that it will invest approximately 400 million euros a year to establish the first mRNA vaccine center of excellence (Center of Excellence) .
Note: The original text has been deletedReference materials:[1] Sanofi launches dedicated vaccines mRNA Center of Excellence.
-
New progress in oral SERD: Sanofi and Eli Lilly announce test results
Time of Update: 2021-08-10
Breast cancer patients have previously received at least 2 lines of treatment, including the endocrine drug Fulvestrant (46%), CDK4/6 inhibitors (83%) and chemotherapy (33%) .
-
You can see the popularity of the "magic medicine" Pien Tze Huang, and see the plight of proprietary Chinese medicine behind the virtual fire
Time of Update: 2021-08-10
However, when we re-examine the Chinese medicine companies represented by Zhangzhou Pien Tze Huang, this problem seems to be more prominent.
For Chinese patent medicines, centralized procurement puts even more pressure on Chinese medicine companies, and the core of the pressure is price .
-
The results of the fifth batch of centralized procurement are announced!
Time of Update: 2021-08-10
According to the provisions of the fifth batch of national drug procurement documents, the procurement cycle of selected drugs can be up to 3 years, and the procurement volume can be up to 80% of the agreed procurement volume .
-
How to divide the “ten billion cake” of the fourth domestically-made bevacizumab biosimilar drug approved?
Time of Update: 2021-08-10
On June 22, Hengrui Medicine's bevacizumab biosimilar was approved in China for the indications of metastatic colorectal cancer and advanced, metastatic or recurrent non-small cell lung cancer .
-
The fifth batch of countries organized the centralized procurement of medicines to produce the results of the proposed selection
Time of Update: 2021-08-10
Since the establishment of the National Medical Insurance Bureau, it has carried out 5 batches of centralized drug procurement, covering 218 varieties, and involving a market capacity of 220 billion yuan .
-
GlaxoSmithKline cancels its "Pharmaceutical Business License" in China
Time of Update: 2021-08-10
FinishingrainbowYesterday (June 28), Shanxi Pharmaceutical Equipment Centralized Bidding and Purchasing Network issued a notice showing that the "Drug Business License" of GlaxoSmithKline (China) Investment Co.
It is understood that on June 23, GSK announced the split of its consumer healthcare business merged with Pfizer and established "New GlaxoSmithKline" .
-
EGFR inhibitor development home: target degradation
Time of Update: 2021-08-10
Generations of EGFR-TKIs have brought us unlimited imagination, but cancer cells will always come back due to mutations and drug resistance .
-
PD-1 inhibitors Opdivo and Keytruda are approved for new indications in the EU
Time of Update: 2021-08-10
For Bristol-Myers Squibb, the European Commission has approved Opdivo and Yervoy immunocombination therapy for the treatment of previous fluoropyrimidine-containing combined chemotherapy, tumors with mismatch repair defects (dMMR) or high microsatellite instability (MSI-H) Of adult patients with metastatic colorectal cancer (mCRC) .
-
Foresite, Gilead and others acquire new crown antiviral drugs in a $250 million SPAC transaction
Time of Update: 2021-08-10
On June 29, according to foreign media reports, Foreste Capital announced that it would use one of its SPACs (special purpose mergers and acquisitions company) to list Pardes Biosciences, which was established only last year .
-
Tianyao's methylprednisolone sodium succinate for injection passed the consistency evaluation
Time of Update: 2021-08-10
("Jinyao Pharmaceutical") received approval and issuance from the State Food and Drug Administration regarding methylprednisolone sodium succinate for injection (40mg).
-
Tosunshine: Atorvastatin calcium tablets, a holding subsidiary, obtained a drug registration certificate
Time of Update: 2021-08-10
Atorvastatin calcium is a selective and competitive inhibitor of HMG-CoA reductase.
It reduces plasma cholesterol and lipoprotein levels by inhibiting the synthesis of HMG-CoA reductase and cholesterol in the liver, and increases the surface of liver cells.
